PHCentral News is gathered daily to bring you the latest developments in pulmonary hypertension treatments and research as well as stories we think are useful on an array of topics. Under current news, you will find a dynamic list of stories for the last thirty (30) days. You will find older news stories in our archives. Stories about specific treatments can also be found in the medical section.
If you run across a PH news story we've missed or important story with broad appeal, please send us the link and we'll make sure it gets added. Send news: contact/info+phcentral+org.
- August 30, 2015
- 9-month-old baby born with 5 holes in heart, 3D printed heart models help surgeons save his life
Medical 3D printing innovations are slowly but steadily changing the medical landscape, but there is one among them that is already saving lives on a remarkable scale. It’s also the simplest, but no less important: 3D printed replica models of organs or fractures that can be used by doctors to prepare complex and unusual surgeries. The importance of this technique is again illustrated by Chinese doctors in Nanjing, China. There, the nine-month-old boy Chen Chen has just undergone successful and crucial heart surgery that had been prepared with the help of 3D printed heart replicas.
- August 28, 2015
- Mechanism of Resveratrol Action in PAH Identified by Study
(Lung Disease News)
Researchers at Peking Union Medical College Hospital in Beijing discovered a novel pathway of cell cycle regulation in pulmonary arterial hypertension (PAH) disease progression. A collection of experiments described in the researcher’s study, “Regulation of Cell Cycle Regulators by SIRT1 Contributes to Resveratrol-Mediated Prevention of Pulmonary Arterial Hypertension,” demonstrated that Silence Information Regulator 1 (SIRT1) signaling is implicated in PAH and is the pathway of action for resveratrol-mediated attenuation of PAH.
- UK's NICE Recommends Once-daily LIXIANA® (Edoxaban) for the Treatment and Prevention of Recurrent Deep Vein Thrombosis and Pulmonary Embolism in Adults
The National Institute for Health and Care Excellence (NICE), the medicines cost-effectiveness body for England and Wales, has today recommended a new treatment to help patients suffering from blood clots in the legs and lungs.
- August 27, 2015
- New Method of Evaluating Right Ventricular Function Predicts Pulmonary Arterial Hypertension Outcome in Patients
(Lung Disease News)
People with pulmonary hypertension have high blood pressure in the lung arteries rather than in regular circulation. The disease can be caused by several other conditions and diseases, including connective tissue disease, congenital abnormalities of the heart, emphysema, and fibrosis in the lungs. Regardless of what leads to its development, pulmonary hypertension is a serious disease that is difficult to treat. Many patients require a heart-lung transplant, medications to control the high blood pressure in the lungs, and some die from their disease. The median life expectancy for those with PH who remain untreated is 2.8 years.
- Researchers Discover Reduced Left Ventricular Function in Children With Pulmonary Hypertension
(Pulmonary Hypertension News)
Results from a recent study published in the journal Circulation: Cardiovascular Imaging showed that pediatric patients with Pulmonary hypertension have reduced Left Ventricular strain/strain rate, predominantly within the septum, with relationships to invasive hemodynamics, right ventricular strain, and functional Pulmonary hypertension measures
- August 26, 2015
- udy Shows 6-Month Warfarin Treatment Insufficient For Treating PE Aggravated by Obstructive Sleep Apnea Hypopnea Syndrome
(Pulmonary Hypertension News)
A new study recently published in the Chinese Medical Journal revealed that a 6-month warfarin treatment might not be sufficient as an effective therapy for patients with pulmonary embolism complicated by obstructive sleep apnea hypopnea syndrome (OSAHS). The study was conducted by researchers at Beijing Anzhen Hospital in China and is entitled “Obstructive Sleep Apnea Hypopnea Syndrome as a Reason for Active Management of Pulmonary Embolism.”
- August 25, 2015
- Individual treatment a must for PAH patients
Kris Ross, an ambassador with the Pulmonary Hypertension Association of Canada, is advocating against a one-size-fits-all approach for a life-threatening rare lung disease, on Thursday August 20, 2015 in Cornwall, Ont. Todd Hambleton/Cornwall Standard-Freeholder/Postmedia Network.
- August 24, 2015
- Highlights on New Theory for Pulmonary Arterial Hypertension: The Metabolic Theory
(Pulmonary Hypertension News)
Researchers at the University of Alberta in Canada published an article in the journal Cell Metabolism concerning pulmonary arterial hypertension (PAH) and details on a new theory suggesting that the disorder should be seen as a syndrome affecting several organs at the metabolic level. The study is entitled “The Metabolic Basis of Pulmonary Arterial Hypertension.”
- August 23, 2015
- Left Ventricular Myocardial Function in Children With Pulmonary Hypertension
Through ventricular interdependence, pulmonary hypertension (PH) induces left ventricular (LV) dysfunction. We hypothesized that LV strain/strain rate, surrogate measures of myocardial contractility, are reduced in pediatric PH and relate to invasive hemodynamics, right ventricular strain, and functional measures of PH.
- August 22, 2015
- Iloprost may ease Raynaud’s syndrome, prevent digital ulcers
Iloprost outperformed alprostadil in treating secondary Raynaud’s syndrome and may prevent digital ulcers from developing, according to study findings.
- August 21, 2015
- Health: Anemia is a complicated condition with many causes
Many people assume they are anemic if they are experiencing a lot of fatigue. However, fatigue is a common symptom of many disorders.
- Novel treatment target found for RV failure in PAH
Researchers have identified a molecular pathway by which downregulation of microRNA (miR)-126 contributes to right ventricular (RV) failure in patients with pulmonary arterial hypertension (PAH).
- August 20, 2015
- Low GLSRV heralds adverse outcomes in PAH patients
Impaired global longitudinal strain of the right ventricle (GLSRV) predicts adverse outcomes in patients with pulmonary arterial hypertension (PAH), say investigators.
- August 19, 2015
- Autoantibody status fails to predict death risk in systemic sclerosis with PAH
Anticentromere and isolated nucleolar autoantibodies are prevalent in systemic sclerosis (SSc) patients with pulmonary arterial hypertension (PAH), but they do not predict survival, US research shows.
- August 18, 2015
- Resveratrol May Prevent Pulmonary Arterial Hypertension Development
(Pulmonary Hypertension News)
A new study led by researchers at Peking Union Medical College Hospital in China recently revealed that resveratrol can prevent pulmonary arterial hypertension (PAH) through a protein called SIRT1 (silence information regulator 1)...
Researchers found that human PASMCs and rat models of PAH had a significantly decreased SIRT1 expression...
Resveratrol was found to attenuate the pulmonary arterial remodeling and decrease pulmonary arterial pressure in PAH rat models...
The research team concluded that SIRT1 plays a key role in PAH prevention by resveratrol as it mediates the regulation of expression of cell cycle regulatory molecules.
- Early surgery for mitral regurgitation, before clinical triggers emerge, has best outcomes
About 2% of the U.S. population has mitral valve regurgitation, which left untreated, can remain mild or lead to arrhythmia or heart failure. Timing of surgery is a matter of controversy, with guidelines suggesting "watchful waiting" or medical treatment until heart failure or poor function becomes apparent. Now a report in the Journal of Thoracic and Cardiovascular Surgery, the official publication of the American Association for Thoracic Surgery (AATS), finds that allowing patients to reach these "surgical triggers" doubles the risk of postoperative mortality and heart failure compared to those who undergo early surgery.
- August 17, 2015
- Researchers identify new drug target for serious heart and lung condition
(Imperial College London)
The research team, led by Professor Martin Wilkins and Dr Lan Zhao from the Department of Medicine at Imperial College London, have identified a gene that is switched on in the blood vessels of the lung in pulmonary hypertension. Disabling this gene helps protect against pulmonary hypertension in low oxygen conditions. The team believe this provides a clue for a new treatment approach to PAH.
- What’s lurking in your lungs? Surprising findings emerge from U-M microbiome research
With every breath you take, microbes have a chance of making it into your lungs. But what happens when they get there? And why do dangerous lung infections like pneumonia happen in some people, but not others?
- August 16, 2015
- Pirfenidone (Esbriet) Shown As Safe, Effective in Daily Clinical Practice Treatment of IPF
(Pulmonary Hypertension News)
Results from a recent study published in the journal Advance Therapy, showed that pirfenidone (known by the brand name Esbriet from Roche) is effective and has a safety profile consistent with those seen in the Phase III clinical study ASCEND for the treatment of IPF. According to the researchers, these results highlight the benefits and challenges related to treatment with pirfenidone.
- August 15, 2015
- Beating Heartburn with Pulmonary Hypertension
(Pulmonary Hypertension RN)
Heartburn or gastro-esophageal reflux disease (GERD) is a very common symptom for patients with pulmonary hypertension. Patients may experience chest tightness, burning, pressure or even cough and hoarseness. Often symptoms are worse after eating certain foods or lying down at night.
- Single Low-magnitude Electric Pulse Successfully Fights Inflammation
The Feinstein Institute for Medical Research, the research arm of the North Shore-LIJ Health System, and SetPoint Medical Inc., a biomedical technology company, released the results of research on the therapeutic potential of vagus nerve stimulation. In a paper published by Bioelectronic Medicine, Kevin J. Tracey, MD, and his colleagues at the Feinstein Institute, explore how low-level electrical stimulation interacts with the body's nerves to reduce inflammation, a fundamental goal of bioelectronic medicine.
- August 14, 2015
- Pulmonary hypertension: A growing problem in US children
A review of 15 years' worth of data in a national pediatric medical database has documented a substantial increase in the rate of hospitalizations for children with a form of high blood pressure once most common in those with congenital heart disease.
- Current Diagnostic Criteria for COPD Inadequate, Experts Say
Current chronic obstructive pulmonary disease (COPD) management programs and guidelines overdiagnose elderly patients and underdiagnose young ones. An analysis published online July 1 in the BMJ details the problem and calls for the adoption of lower limits of normal (LLN) criteria for airflow obstruction that are specific for different populations.
- August 13, 2015
- Pulmonary Hypertension Type Predicts TAVR Outcome, Could Help Select Candidates
When selecting patients for TAVR, stratifying those with pulmonary hypertension (PH) according to hemodynamic presentation can more accurately predict acute treatment response and 1-year mortality, according to a study published online July 8, 2015, in Circulation: Cardiovascular Interventions.
- August 12, 2015
- The zinc transporter ZIP12 regulates the pulmonary vascular response to chronic hypoxia
The typical response of the adult mammalian pulmonary circulation to a low oxygen environment is vasoconstriction and structural remodelling of pulmonary arterioles, leading to chronic elevation of pulmonary artery pressure (pulmonary hypertension) and right ventricular hypertrophy. Some mammals, however, exhibit genetic resistance to hypoxia-induced pulmonary hypertension.
- Pulmonary Arterial Hypertension Market Expected to Expand due to Rise in Incidence of Heart Failures
The global pulmonary arterial hypertension market is expected to rise proportionate to the rise in the number of heart failures. Pulmonary arterial hypertension is characterized by restrained blood flow via the pulmonary arteries, which leads to a constant increase in pulmonary vascular resistance and finally failure of the right side of the heart. PAH is one of five groups of pulmonary hypertension, as described by the World Health Organization (WHO). PAH develops due to the narrowing, blocking, and thickening of the pulmonary arteries.
- August 11, 2015
- Selective enhancement of endothelial BMPR-II with BMP9 reverses pulmonary arterial hypertension.
Genetic evidence implicates the loss of bone morphogenetic protein type II receptor (BMPR-II) signaling in the endothelium as an initiating factor in pulmonary arterial hypertension (PAH). However, selective targeting of this signaling pathway using BMP ligands has not yet been explored as a therapeutic strategy. Here, we identify BMP9 as the preferred ligand for preventing apoptosis and enhancing monolayer integrity in both pulmonary arterial endothelial cells and blood outgrowth endothelial cells from subjects with PAH who bear mutations in the gene encoding BMPR-II, BMPR2.
- August 10, 2015
- Trends in Hospitalization for Pediatric Pulmonary Hypertension
Pulmonary hypertension (PH) has been associated with substantial morbidity and mortality in children, but existing analyses of inpatient care are limited to small single-institution series or focused registries representative of selected patient subgroups. We examined US national data on pediatric PH hospitalizations to determine trends in volume, demographics, procedures performed during admission, and resource utilization.
- August 9, 2015
- Sunshine Heart Provides Update on Fully Implantable Circulatory Support System
Sunshine Heart (NASDAQ:SSH) announced today an update on its next generation, fully implantable version of the Company's flagship C-Pulse® technology. Sunshine Heart is pleased to report that it will commence a first-in-human study using the novel transcutaneous energy transmission (TET) system and a new smaller implantable pump in Q3 2016.
- August 8, 2015
- Finding Pulmonary Hypertension before it's too late
We hear a lot of concern about hypertension, or high blood pressure, but there is a similar, perhaps greater concern that can sneak up on you too. It's called Pulmonary Arterial Hypertension when the blood is having trouble pushing into the lungs.
- August 7, 2015
- 7 Avoidable Habits That Cause Fatal Respiratory Disorders
The respiratory system plays a critical role in the proper functioning of the body. It comprises the nose externally, trachea (or windpipe), bronchi as well as a branching network of bronchioles which open into the alveoli (air sacs) within the lung tissue. This system is involved in the exchange of gases, notably oxygen and carbon dioxide at the level of the alveoli. Needless to mention that oxygen which we breathe in is essential for the survival of body tissues which in turn generate carbon dioxide as a by-product of metabolism that must be expelled from the body through the lungs.
- August 6, 2015
- Meta-analysis: Exercise training benefits patients with pulmonary hypertension
Exercise training is safe and effective for patients with pulmonary hypertension, according to a meta-analysis published in Circulation: Heart Failure.
- August 5, 2015
- New Case-Study Highlights PAH-associated with Systemic Lupus Erythematosus
(Pulmonary Hypertension News)
In a recent study entitled “Lupus-Associated Pulmonary Arterial Hypertension: Variable Course and Importance of Prompt Recognition”, researchers present a case study of a young woman with systemic lupus erythematosus (SLE) exhibiting pulmonary arterial hypertension, a potentially lethal SLE-manifestation. They highlight the need for a prompt recognition of PAH in SLE patients so that effective treatment can be introduce promptly and prevent SLE patients’ deaths. The study was published in the journal Case Reports in Medicine.
- August 3, 2015
- Epigenetic modulation as a therapeutic approach for pulmonary arterial hypertension
Abstract: Pulmonary arterial hypertension (PAH) is a rare but progressive and currently incurable disease, which is characterized by vascular remodeling in association with ...
- Pro-inflammatory Signature of the Dysfunctional Endothelium in Pulmonary Hypertension: Role of MIF/CD74 Complex
Inflammation and endothelial dysfunction are considered two primary instigators of pulmonary arterial hypertension (PAH). CD74 is a receptor for the pro-inflammatory cytokine macrophage migration-inhibitory factor (MIF). This ligand/receptor complex initiates survival pathways and cell proliferation, triggers the synthesis/secretion of major pro-inflammatory factors and cell adhesion molecules. Objectives: We hypothesized that MIF/CD74 signaling pathway is over-expressed in idiopathic PAH (iPAH) and contributes to a pro-inflammatory endothelial cell (EC) phenotype.
- August 2, 2015
- VTE Risk Tripled in Systemic Sclerosis
Patients with systemic sclerosis (SSc) have an overall threefold increased risk of venous thromboembolism (VTE), with the highest risks being seen during the first year after diagnosis, a Canadian population-based study found.
- Coffee roasters' health at risk from chemical compound
Editor's note: Next time you hang out at your favorite coffee roasting spot, consider this. Perhaps it would be wise to get your cup to go.
CHEMICAL COMPOUND DIACETYL IS A HAZARD—AND COFFEE ROASTERS DON’T EVEN REALIZE IT
- Airway-Centered Interstitial Fibrosis
ACIF is an interstitial lung disease with a better survival when compared with IPF. The main etiologies are HP and GERD. The oxygen saturation at rest, the presence of cough and some histological findings are predictors of survival.
- August 1, 2015
- Echocardiography and Pulmonary Arterial Hypertension: A Detailed Look
(Pulmonary Hypertension RN)
Echocardiogram (or echo) is an ultrasound-based test that can tell us a great deal about your heart. By bouncing and receiving ultrasound waves off your heart and adjacent structures, we can generate images of your heart. We can learn about the size and function of the right and left side of your heart and the valves. We can estimate pressures but not directly measure pressures. As we have emphasized in many different places on this website, an echocardiogram is not a substitute for a right heart catheterization. The diagnosis of PAH should never be made without a right heart catheterization and treatment should not be started until after a right heart catheterization is completed. Let’s take a more detailed look at the components of the echocardiogram report.
- Hepatopulmonary Syndrome and Portopulmonary Hypertension
Hepatopulmonary syndrome and portopulmonary hypertension are cardiopulmonary complications, which are not infrequently seen in patients with liver disease and/or portal hypertension. These entities are both clinically and pathophysiologically different: the hepatopulmonary syndrome is characterized by abnormal pulmonary vasodilation and right-to-left shunting resulting in gas exchange abnormalities, whereas portopulmonary hypertension is caused by pulmonary artery vasoconstriction leading to hemodynamic failure.